<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31662">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01736618</url>
  </required_header>
  <id_info>
    <org_study_id>BSC CRM CDM00055718</org_study_id>
    <secondary_id>BSC CRM CDM00055718</secondary_id>
    <nct_id>NCT01736618</nct_id>
  </id_info>
  <brief_title>S-ICD® System Post Approval Study</brief_title>
  <official_title>S-ICD® System Post Approval Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cameron Health, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cameron Health, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the S-ICD Post Approval Study is to document long term safety and
      effectiveness outcomes associated with the implantation of the SQ-RX pulse generator and
      Q-TRAK electrode in a commercial clinical setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The S-ICD Post Approval Study is a non-randomized registry that will retrospectively enroll
      subjects who participated in the S-ICD Clinical Investigation (IDE G090013) and
      prospectively enroll new candidates for the S-ICD System.  The target enrollment sample size
      is 1,616 subjects at up to 150 investigational sites to achieve 1,025 subjects in the
      analysis cohort at 60 months.

        -  The primary safety endpoint of the study is the Type I (caused by the S-ICD System)
           Complication Free Rate at 60 months compared to a performance goal of 85%.

        -  The primary effectiveness endpoint is the Overall Shock Effectiveness in Converting
           Spontaneous Discrete Episodes of VT/VF through 60 months compared to a performance goal
           of 94%.

        -  The secondary safety endpoint of the study is the Electrode-Related Complication Free
           Rate at 60 months compared to a performance goal of 92.5%.

        -  The secondary effectiveness endpoint is First Shock Effectiveness in Converting Induced
           (Acute) and Spontaneous Discrete Episodes of VT/VF through 60 months compared to a
           performance goal of 84.0%.

      Additional objectives include characterization of long term safety and effectiveness in
      subjects of varied body habitus and in traditionally underrepresented populations.

      Subjects must meet the following criteria to be eligible for inclusion in the study:

        1. Eligible for implantation with an S-ICD System, OR previously implanted with an S-ICD
           System in the S-ICD System Clinical Investigation (IDE G090013)

        2. Willing and able to provide written informed consent or have informed consent provided
           by a legal representative

      Subjects who meet the following criteria must be excluded from the study:

      1. Remaining life expectancy of less than 360 days

      Enrolled subjects will be followed at the implant procedure, predischarge and annual(±60
      days) follow-up visits.  Subjects are followed according to the standard of care at their
      participating investigational center.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort</study_design>
  <primary_outcome>
    <measure>Type I Complication Free Rate</measure>
    <time_frame>60 months (1800 days)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Type I complications are adverse events caused by a component of the S-ICD System (i.e. pulse generator, electrode, EIT or programmer) that results in permanent loss of device function, invasive intervention or death.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Shock Effectiveness in Converting Spontaneous Discrete Episodes of VT/VF</measure>
    <time_frame>60 months (1800 days)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall shock effectiveness refers to conversion of an episode following on any of the 5 shocks (maximum) that may be delivered during a single episode.  Discrete episodes of VT/VF are those that are temporally independent (&lt;3 within a 24 hour period), unlike storm episodes, which occur in clusters (≥3 episodes within a 24 hour period).  Episodes that spontaneously terminate will be excluded from this endpoint since the effectiveness of the shock cannot be evaluated in such circumstances.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Electrode-Related Complication Free Rate.</measure>
    <time_frame>60 months (1800 days)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>A complication is an adverse event that results in permanent loss of device function, invasive intervention or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First Shock Effectiveness in Converting Induced (Acute) and Spontaneous Discrete Episodes of VT/VF</measure>
    <time_frame>60 months (1800 days)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Freedom from complications requiring surgical revisions of the pulse generator or electrode, including pocket revisions, surgical repositioning or removal of the device in response to product performance issues</measure>
    <time_frame>60 months (1800 days)</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Individual rates of each adverse event category contributing to the primary and secondary safety endpoints</measure>
    <time_frame>60 months (1800 days)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Will be examined including two-sided 95% exact confidence intervals</description>
  </other_outcome>
  <other_outcome>
    <measure>All cause mortality</measure>
    <time_frame>60 months (1800 days)</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Electrical performance data recorded by the device</measure>
    <time_frame>60 months (1800 days)</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Mechanical electrode failures</measure>
    <time_frame>60 months (1800 days)</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Explants and causes</measure>
    <time_frame>60 months (1800 days)</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Transvenous ICD (TV-ICD) implantation following subcutaneous ICD (S-ICD) explant</measure>
    <time_frame>60 months (1800 days)</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Surgical revisions in response to suboptimal placement or system movement</measure>
    <time_frame>60 months (1800 days)</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Chronic pain/discomfort requiring surgical intervention</measure>
    <time_frame>60 months (1800 days)</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Removal of S-ICD System in response to implant testing</measure>
    <time_frame>60 months (1800 days)</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Syncope associated with VT/VF episodes</measure>
    <time_frame>60 months (1800 days)</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Inappropriate shock incidence</measure>
    <time_frame>60 months (1800 days)</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Premature battery depletions and other device malfunctions</measure>
    <time_frame>60 months (1800 days)</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1616</enrollment>
  <condition>Primary Prevention of Sudden Cardiac Arrest</condition>
  <condition>Secondary Prevention of Sudden Cardiac Arrest</condition>
  <arm_group>
    <arm_group_label>S-ICD System Implant Attempt</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>S-ICD System</intervention_name>
    <arm_group_label>S-ICD System Implant Attempt</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The S-ICD System is intended to provide defibrillation therapy for the treatment of
        life-threatening ventricular tachyarrhythmias in patients who do not have symptomatic
        bradycardia, incessant ventricular tachycardia, or spontaneous, frequently recurring
        ventricular tachycardia that is reliably terminated with anti-tachycardia pacing.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligible for implantation with an S-ICD System, OR previously implanted with an S-ICD
             System in the S-ICD System Clinical Investigation (IDE G090013)

        AND

          -  Willing and able to provide written informed consent or have informed consent
             provided by a legal representative

        Exclusion Criteria:

          -  Remaining life expectancy of less than 360 days
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michael P Husby, MS, MPH</last_name>
    <phone>312-402-1877</phone>
    <email>michael.husby@bsci.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Huntsville Hospital</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jay Dinerman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Arrhythmia Consultants, PLC</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thomas Mattioni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Silicon Valley Cardiology</name>
      <address>
        <city>East Palo Alto</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>R. Hardwin Mead</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sharp Grossmont Hospital</name>
      <address>
        <city>El Cajon</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Peter Belott</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Micael Cao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huntington Memorial Hospital/Foothill Cardiology</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mayer Rashtian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sharp Memorial Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>M. Charles Athill</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. John's Health Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Shephal Doshi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Torrance Memorial Medical Center/Pulsa Arrhythmia Group</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Erol Kosar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Manish Shah</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Angel Leon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gwinnett Medical Center</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Niraj Sharma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bradley Knight</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Martin Burke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advocate Health and Hospitals Corporation/Midwest Heart Foundation</name>
      <address>
        <city>Lombard</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Moeen Saleem</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Parkview Research Center</name>
      <address>
        <city>Ft. Wayne</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Mirro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Claudio Schuger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abbott Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Charles Gornick</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cooper University Hospital</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrea Russo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novant Health Heart and Vascular</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mark Kremers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Forsyth Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Drucker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Summa Health</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Pelini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mark Niebauer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Raul Weiss</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Toledo Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Johan Aasbo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Fermin Garcia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Drexel Hahnemann University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Steven Kutalek</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Gold</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ted Friehling</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sentara Cardiovascular Research Institute</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>John Herre</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kristen Patton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kootenai Heart Clinics</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Timothy Lessmeier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Vancouver Clinic</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Robert Swenson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 29, 2014</lastchanged_date>
  <firstreceived_date>November 27, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>subcutaneous implantable defibrillator post approval study sudden cardiac arrest Cameron Health defibrillator</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Arrest</mesh_term>
    <mesh_term>Death, Sudden, Cardiac</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
